Management/Scientific Team

Billy small

Jack V. Talley – CEO 

Jack V. Talley is a pharmaceutical management professional with more than 30 years of experience in the industry. He has taken three companies     successfully public.  He has been responsible for more than 20 equity issuances in both the private and public sectors raising in aggregate in excess of $100 million.  Two of the three companies he has taken public have been successfully sold, the third is still independent.  He has been responsible for numerous business development transactions and has secured product approvals in both Europe and the United States for a wide variety of investigational drugs.  Most recently he was the President, CEO and a member of the Board of Directors for Alissa Pharma, LLC a privately held company focused on antibody directed isotopes for various forms of cancer.  Previously he was the CEO, President and a Director of Actinium Pharmaceuticals, Inc. (API) which he took public. Mr. Talley joined API from the position of President, Chief Executive Officer and a Director at EpiCept Corporation which he also took public.  Prior to EpiCept, Mr. Talley was the Chief Executive Officer of Consensus Pharmaceuticals, Inc., a biotechnology drug discovery start-up company that developed a proprietary peptide-based combinatorial library screening process. Prior to joining Consensus, Mr. Talley led Penwest Ltd.’s efforts in its IPO spin-off of its subsidiary Penwest Pharmaceuticals Co. in 1998 and served as President and Chief Operating Officer of Penwest Pharmaceuticals. Penwest was eventually acquired by Endo.  Mr. Talley led the alliance between Penwest and Endo.  Mr. Talley started his career at Sterling Drug Inc., where he was responsible for all U.S. marketing activities for prescription drugs when the company was merged with Sanofi, he launched various new pharmaceutical products and participated in the 1988 acquisition of Sterling Drug by Eastman Kodak Co. Mr. Talley received his B.S. in Chemistry from the University of Connecticut and completed coursework towards an M.B.A. in Marketing from New York University, Graduate School of Business.
Billy small

William Z. Levine, DDS – Executive Chairman and Founder

Bill is the director and founder of the Jerusalem Perio Center, the largest and foremost private healthcare facility specializing in the treatment of oral diseases and implantology in Israel. A Diplomate of the American Board of Periodontology with seven registered patents, Dr. Levine is a practicing periodontist with over 20 years of clinical experience, and a frequently featured speaker at international forums on periodontal disease and implantology. Dr. Levine is an active board member of several hospitals and healthcare centers in Israel. He received his DDS and Certificate of Periodontology at Columbia University, New York.

 

 

Les

Leslie Kraus – CFO/COO

Les Kraus commenced as COO of Izun in 2013. For the 12 years prior to this, Les served as Chief Financial Officer of Retail Apparel Group Pty Ltd (RAG), the largest menswear retailer in Australia. During his time at RAG, Les managed two sale processes to private equity firms. He is a qualified Chartered Accountant in Australia and has over 30 years of operational and financial experience within the clothing industry, covering both retail and wholesale businesses.

 

 

 

gabeGabriel Nussbaum, MD, PhD – Director of Scientific Affairs

Gabe joined the Izun team in 2004 and continues to be instrumental in the development of Izun’s products.  A basic science researcher and clinician, Gabe is a US board-certified physician for internal medicine and has performed graduate studies and post-doctoral research in inflammation at the Weizmann Institute of Science, an international center of scientific research in Rehovot, Israel. Dr. Nussbaum has numerous publications.

 

 

 

amyAmy Rosenbluh, PhD – Director of Production, Laboratory Director

Amy joined Izun in 2006, initially as Director of the R&D and QC Laboratory, and has since added Director of Production to her responsibilities.  Amy obtained her Master’s degree from Harvard University and her Ph.D. from Tel Aviv University in Israel, with post-doctoral fellowships at both Stanford University and the Weizmann Institute of Science in Rehovot, Israel. Amy brings to Izun rich experience in academic research and in managerial positions, both in academia and in the private sector. Dr. Rosenbluh holds a patent and has published a chapter in a book as well as numerous articles.

 

 

 

Ronald Stern – EVP Marketing & Product Development

Ron has accumulated extensive experience in strategic marketing and positioning, particularly for innovative, new products. After majoring in Marketing and Finance at Lehigh University, he joined Thompson Medical Company (TMC) in 1977 as a New Product Manager. Over the years, Mr. Stern advanced at TMC to the position of President of the Nutritional Division and, when the Slim-Fast Foods Company was spun off from TMC in the late 1980s, he was promoted and eventually assumed the role of Company President in 1995. Mr. Stern held this position until the Slim Fast Foods Company was sold to Unilever in 2000, after which he was retained as a consultant by Unilever until 2003.